NCT04630613Recruiting

NOX4 and Related Biomarkers in ADPKD

Mayo Clinic

Start Date

7/21/2020

Completion Date

1/1/2027

Summary

To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).

Detailed Description

This will be a cross sectional study and will include male and female, young (15-40-years) well characterized patients with early (eGFR\>70mL/min/1.73m2) ADPKD. Patients with different classes of disease severity will be selected using the ADPKD imaging classification. The study will include 60 class-1 (A-E) patients (N=12 per each sub-class).

Eligibility Criteria

Age Range: 15 years to 40 years

Inclusion Criteria: * ADPKD (based on Ravine et al. criteria) * Class 1 A-E according to imaging classification * Male and female subjects 15 - 40 years of age * Estimated GFR\> 70 mL/min/1.73 m2 (CKD-EPI) * Ability to provide written, informed consent Exclusion Criteria: * Class 2 according to imaging classification * Concomitant systemic disease affecting the kidney * Diabetes mellitus * Predicted urine protein excretion in \>1 g/24 hrs * Use of antioxidants i.e. vitamins, Nrf2 activators * Abnormal urinalysis

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Autosomal Dominant Polycystic Kidney Disease

Locations

Mayo Clinic

Rochester, Minnesota 55905

United States